| Class | Heparin reversal agent |
|---|---|
| Chemistry |
Sperm nuclear polypeptide
|
| Routes of administration |
Intravenous only |
| Absorption |
Minimal oral bioavailability
|
| Solubility |
pKa = 9.2-13.3, based on the pKa for lysine and arginine, the major amino acid constituents (>67%) of protamine. Sparingly soluble in sterile water, adjusted to a pH of 6.0-7.0 with dibasic sodium phosphate (heptahydrate) and/or sulfuric acid.
|
| Distribution |
VOD probably about 0.2-1.0 L/kg; it is not protein bound as such, but it does bind to heparin
|
| Metabolism |
Protamine alone is cleared renally; protamine-heparin complexes are detected and removed from the circulation by hepatic reticuloendothelial macrophages.
|
| Elimination |
Rapidly cleared from the bloodstream, whether it was bound to heparin or not, partly by reticuloendothelial degradation, partly by tissue binding, and partly by renal excretion
|
| Time course of action |
Plasma half-life is about 5-10 minutes
|
| Target receptor |
Plasminogen-fibrin complex |
| Mechanism of action |
Protamine is a highly cationic polypeptide and binds the anionic heparin, creating an inert stable complex that has no anticogulant activity. |
| Clinical effects |
- reversal of heparin - rebound re-heparinisation because of short half-life - occasional anaphylaxis |
| Literature reference | |
| CICM details of understanding | Level 3 |
| Mentioned around Deranged Physiology | |
| Related SAQs |
Question 15 from the first paper of 2022 (Second Part Exam) |